Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06920108

TRACE4BUS for BI-RADS Classification

The purpose of this clinical study is to evaluate the use of the TRACE4BUS software that is proposed to support the physician in reporting the results of breast ultrasound according to the international classification standard Breast Image - Reporting and Data System (BI-RADS) of the American College of Radiology. This classification is recommended because it reduces the risk of subjective interpretations of descriptive results and prevents these results from being interpreted differently by the physician who evaluated the ultrasound examination, the physician who may have requested the examination, the patient and the patient's trusted physician (family physician or specialist). The BI-RADS classification is based on the evaluation of the shape, size, margins and other characteristics of a possible breast abnormality identified on the ultrasound image by the physician who evaluated the ultrasound examination, characteristics that are not always easy for that physician to evaluate.

The study aims to verify if the BI-RADS classification by the physician can be supported by the TRACE4BUS software. In particular, it refers to the support that the software provides to the physician who has evaluated the ultrasound examination in assigning the BI-RADS category for an abnormality of the breast found to be suspicious by the physician on the basis of qualitative characteristics (shape, size, margins, preferential orientation with respect to the skin plane, internal homogeneity/inhomogeneity, possible acoustic barrier effect, etc.). The TRACE4BUS software, trained on the basis of hundreds of ultrasound images of suspicious breast masses with a certain diagnosis of benignity or malignancy at subsequent diagnostic investigations, performs a quantitative analysis of the ultrasound characteristics of a suspicious breast mass and proposes a BI-RADS category to the physician. In any case, the physician will have complete decision-making power in the final attribution of the BI-RADS category and in the subsequent recommendations or decisions regarding the medical management of the case.

The clinical study also aims to evaluate whether the agreement between physicians in the use of this BI-RADS classification of suspicious breast masses improves with the use of the software.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–89 year

Sex eligibility

Female

Study type

Observational

Primary location

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Lombardy, 20133, Italy

Location contact

Gianfranco Scaperrotta

CONTACT

[email protected]

+39 333 257 2380

Gianfranco Scaperrotta

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Retrospective study part:
  • Availability of ultrasound-guided breast biopsy and, in case of B3 lesions at needle biopsy, the vacuum-assisted excision, or surgical specimens or a clinical follow-up outcome in at least 12 months subsequent to the biopsy.
  • Prospective study part:
  • Signed informed consent to participate in the study.

Exclusion criteria

  • Retrospective study part:
  • Not availability of ultrasound-guided breast biopsy and, in case of B3 lesions at needle biopsy, the vacuum-assisted excision, or surgical specimens, or a clinical follow-up outcome in at least 12 months subsequent to the biopsy. Age < 18 or > 89 years.
  • Prospective study part:
  • Not availability of Signed informed consent to participate in the study. Age < 18 or > 89 years.

Treatment and study plan

Primary outcomes

  1. Specificity, positive predictive value, sensitivity and negative predictive value

    Time frame: From enrollment to biopsy up to 12-month follow-up when necessary

    Specificity, positive predictive value, sensitivity and negative predictive value before knowing the BI-RADS category proposed by the TRACE4BUS software and after being informed of the software prediction of BI-RADS category by the TRACE4BUS software.

Secondary outcomes

  1. K-Cohen

    Time frame: 9 months and 18 months

    K-Cohen to measure inter-rater agreement between two physicians before knowing the BI-RADS category proposed by the TRACE4BUS software and after being informed of the software prediction of BI-RADS category by the TRACE4BUS software

  2. Number of correct answers on the use of TRACE4BUS as assessed in the training questionnaire

    Time frame: From date of training in the use of TRACE4BUS software to the physicians to training efficacy questionnaire within 2 weeks

    Number of correct answers in the training questionnaire to measure the effectiveness of the training in the use of TRACE4BUS software after one session. More than 70% (0% minimum score, 100% maximum score) of correct answers are required to demonstrate the effectiveness of the training.

  3. Total scores on the usability of TRACE4BUS as assessed in the usability satisfaction questionnaire

    Time frame: 9 months and 18 months

    Total scores on the usability satisfaction questionnaire to measure the usability satisfaction of TRACE4BUS. More than 70% of satisfaction (0% minimum satisfaction, 100% maximum satisfaction) is required to demonstrate the satisfaction on the usability of TRACE4BUS.

Other outcomes

  1. Number of software deficiencies, adverse software effects and adverse events for participants

    Time frame: 9 months and 18 months

Study contacts

Contact information is provided by the study sponsor or research team.

Gianfranco Scaperrotta

CONTACT

[email protected]

+39 333 257 2380

Sponsors and collaborators

Lead sponsor

DeepTrace Technologies S.r.l.

Industry

Registry information

Official study title

TRACE4BUS: Use of the TRACE4BUS Software to Support the Physician in Reporting Breast Ultrasound Results According to the International Classification Standard Breast Image - Reporting and Data System (BI-RADS)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 9, 2025
Registry last updated
Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.